Performance of commercialization strategy, acquisition and merger; Design and explanation of model in Iranian biopharmaceutical industry

Medical or therapeutic biotechnology is the development of research tools, the diagnosis, development and delivery of drugs and vaccines through the use of cellular systems or processes and biological molecules. A very important strategic choice of technology-oriented enterprises in the biopharmaceutical industry is the commercialization strategy. The strategy of purchasing and merging as one of the strategies for commercialization and biomedical drugs has been less considered and researched in the research literature than other strategies. The purpose of this study is to design a comprehensive model of commercialization strategy, merge and acquisition in the country's biopharmaceutical industry based on a consecutive qualitative-quantitative mixed approach. To analyze the research literature, the meta synthesis method and to content validation of the proposed model, the group modeling technique based on the opinion of experts and in a small part based on the survey strategy and the partial least squares technique have been used. The results showed that among the seven categories of predictors, including; Resource complementarity, information asymmetry, experience of alliance between buyer and purchased company, related purchasing experience, cultural, geographical, and business proximity, knowledge and resource transfer (functional, operational, and managerial) and integration process and performance category as The consequence of this strategy, in the bio-pharmaceutical industry of the country, the only issue is the complementarity of resources for companies active in this industry as a predictor.